Key result
TAVR improves functional mitral regurgitation in ~50% of patients, but residual severe MR worsens mortality.
Why the study?
Moderate-to-severe concomitant mitral regurgitation is common in patients undergoing TAVR for severe native aortic stenosis, but its impact has not been uniformly or formally evaluated due to frequent exclusion from landmark TAVR trials.
May warrant closer monitoring of severe MR in TAVR candidates; leaves open whether mitral intervention improves outcomes in randomized trials.
Moderate-to-severe concomitant mitral regurgitation (MR) is not uncommon in patients who undergo transcatheter aortic valve replacement (TAVR) for severe native aortic stenosis (AS). Frequently left untreated, MR improves in severity in approximately half of all patients following TAVR.1 Although the impact of severe MR has not been uniformly and formally evaluated given that it has often been an exclusion criterion in most of the landmark TAVR trials, it has been associated with higher early and late mortality.
No takes yet. Share an insight, caveat, or question.
Sengupta et al. (2020) conducted a review in Severe native aortic stenosis with concomitant functional mitral regurgitation. Transcatheter Aortic Valve Replacement (TAVR) was evaluated. Transcatheter aortic valve replacement (TAVR) improves concomitant functional mitral regurgitation severity in approximately half of patients, though severe MR remains associated with higher mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: